Psychedelic drugs creating hopes for breakthroughs in depression, anxiety, pain and addiction are being tested at UAB. The university is one of a handful in the nation conducting trials with psilocybin, the active ingredient in hallucinogenic mushrooms.
Psychedelic treatments for addiction challenge 12-step’s ideas about what sobriety is: total abstinence from any mood- or mind-altering drug—psychedelics included.
Source: Vice News
Johns Hopkins researchers report that a small number of longtime smokers who had failed many attempts to drop the habit did so after a carefully controlled and monitored use of psilocybin, the active hallucinogenic agent in so-called “magic mushrooms,” in the context of a cognitive behavioral therapy treatment program.
Source: Johns Hopkins
Psychedelic drugs—once promising research subjects that were decades ago relegated to illicit experimentation in dorm rooms—have been steadily making their way back into the lab for a revamped 21st-century-style look. Scientists are rediscovering what many see as the substances’ astonishing therapeutic potential for a vast range of issues, from depression to drug addiction and acceptance of mortality.
Source: Scientific American